Towards Healthcare

Syphilis Testing Companies and Market Trends Analysis

Date : 08 October 2025

Syphilis Testing Companies and Market Forecast

Syphilis Testing Market Companies

Market Forecast

The global syphilis testing market size recorded US$ 2.29 billion in 2024, set to grow to US$ 2.45 billion in 2025 and projected to hit nearly US$ 4.57 billion by 2034, with a CAGR of 6.85% throughout the forecast timeline.

Funding and Investments - Increased investments support R&D for advanced diagnostics and expand testing infrastructure.

  • In January 2025, Bio-Rad Laboratories invested USD 50 million in its molecular diagnostics division to develop new syphilis testing solutions, aiming to enhance its presence in the global infectious disease testing market.

Government and Public Health Initiatives – Screening programs, especially during pregnancy, promote routine testing and support public health goals.

  • In August 2024, Hologic received FDA approval for its Panther Fusion Syphilis Total assay, a fully automated platform designed to improve the accuracy and efficiency of syphilis testing in laboratories.

Syphilis Testing Market Value Chain Analysis

Clinical Trials: Clinical trials in syphilis testing evaluate rapid and point-of-care tests for accuracy and reliability, aiming to improve screening, accelerate diagnosis, and enhance treatment and partner notification across clinical settings.

Regulatory Approvals: Regulatory approval for syphilis tests is overseen by the U.S. Food and Drug Administration (FDA) in the United States and involves ensuring the test's safety and effectiveness through mechanisms like the De Novo pathway for novel devices.

Patient Support and Services: Patient support for syphilis testing involves pre- and post-test counseling, confidential testing at government centers like NACO, and access to at-home test kits. It also includes partner notification and contact tracing services, with some platforms providing free and anonymous options, helping ensure timely treatment and reducing the spread of infection.

Latest Announcement by Industry Leaders

In 2024, NOWDiagnostics, Inc. (NOWDx) launched its First To Know® Syphilis Test nationwide, making it the first FDA-authorized over-the-counter syphilis self-test in the U.S. Available on Amazon and in thousands of pharmacies and retail stores, the test provides accurate in-home results in just 15 minutes using a single drop of blood. Priced under $30, it aims to expand access, reduce stigma, and encourage timely testing. CEO Rob Weigle stated that the test is designed to “break down barriers to healthcare access” and support public health efforts to curb syphilis spread.

Recent Developments in the Syphilis Testing Market

  • In July 2025, Health Canada approved MedMira’s Multiplo® TP/HIV rapid test for investigational use, paving the way for self-testing and non-professional testing. This initiative, supported by clinical research from REACH Nexus, aims to improve early detection and response to the growing cases of HIV and syphilis.
  • In October 2024, Chembio Diagnostics highlighted its DPP® rapid tests, including the HIV-Syphilis combo, at the SCASM conference in La Jolla and the National Conference on Correctional Health Care in Las Vegas. The company emphasized the advantages of point-of-care testing for faster onsite screening in acute care and correctional health settings.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com